VNDA vs. XOMA, VSTM, MACK, RIGL, GOSS, RGLS, LXRX, EBS, ANAB, and VBIV
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include XOMA (XOMA), Verastem (VSTM), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Gossamer Bio (GOSS), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Emergent BioSolutions (EBS), AnaptysBio (ANAB), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings.
In the previous week, XOMA had 12 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 15 mentions for XOMA and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.63 beat XOMA's score of 0.55 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Vanda Pharmaceuticals received 104 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.95% of users gave XOMA an outperform vote.
Vanda Pharmaceuticals has a net margin of 1.30% compared to XOMA's net margin of -886.91%. Vanda Pharmaceuticals' return on equity of 0.46% beat XOMA's return on equity.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vanda Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vanda Pharmaceuticals has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
XOMA has a consensus target price of $57.00, indicating a potential upside of 130.02%. Given XOMA's higher probable upside, analysts clearly believe XOMA is more favorable than Vanda Pharmaceuticals.
Summary
Vanda Pharmaceuticals beats XOMA on 12 of the 17 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
